Nuclear Medicine Market

The global nuclear medicine market is projected to reach USD 21.01 billion by 2030, growing from USD 10.41 billion in 2025, at a CAGR of 15.1% during the forecast period. This growth is due to the increasing prevalence of cancer and cardiovascular diseases; the increasing adoption of hybrid imaging techniques, such as PET/CT and SPECT/CT; and the growing demand for targeted radiopharmaceuticals and radioisotopes. The market is further facilitated by the innovations in radiotracer development and the need for the use of radiotracers in more clinical areas, such as oncology, neurology, and cardiology. Additionally, increasing investments in nuclear medicine infrastructure and substantial reimbursement policies in developed regions are driving adoption globally.

Product innovation and portfolio expansion, strategic collaborations, and acquisitions are some of the dominant strategies adopted by players in the nuclear medicine market. Key players, such as GE HealthCare and Siemens Healthineers, are working on ongoing innovation in imaging systems and radiopharmaceuticals as a way of enhancing their competitive orientation. Simultaneously, companies such as Novartis and Cardinal Health are working toward partnerships, acquisitions, and geographic development to improve production and accessibility worldwide. All the strategies are aimed at helping the participants of the market to respond to the increasing clinical demand while maintaining technological and operational leadership.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the nuclear market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), NTP Radioisotopes SOC Ltd. (South Africa), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), Institutes of Isotopes (Hungary), China Isotope & Radiation Corporation (China), and IRE Elit (Turkey).

GE HealthCare is one of the major players in the nuclear medicine business, with its extensive nuclear pharmacy network and radiopharmaceuticals portfolio approved by the FDA. Its products serve neurological, cardiac, and oncological applications and consist of DaTscan, AdreView, Myoview, Ceretec, Metastron, and Indium 111-based agents. The company enhances access to nuclear medicine diagnostics and therapies and promotes the provision of high-quality patient care worldwide by providing efficient production and distribution of essential radiopharmaceuticals.

Cardinal Health participates in the nuclear medicine market through its Nuclear & Precision Health Solutions business division. The company provides radiopharmaceuticals, generators, and other medical supplies applied in SPECT and PET operations, and operational and regulatory services. Cardinal Health also owns an extensive network of nuclear pharmacies, which prepare and deliver time-sensitive radiopharmaceutical doses to hospitals and imaging facilities. Its nuclear medicine operations are based on reliable supply, compliance, and logistical services for diagnostic and curative purposes.

Market Ranking

The nuclear medicine market is influenced by radiopharmaceutical manufacturers and distribution-oriented healthcare companies that facilitate the diagnostics and therapy processes in the oncology, cardiology, and neurology fields. GE HealthCare plays a central role with its nuclear pharmacy network and portfolio of FDA-approved radiopharmaceuticals, enabling reliable production, preparation, and delivery of diagnostic and therapeutic radioisotopes to healthcare providers. Cardinal Health contributes mainly through its nuclear pharmacy network and distribution capabilities of radiopharmaceuticals, which guarantee the preparation and delivery of radioactive doses in time to the healthcare providers. Curium Pharma concentrates on the production and distribution of diagnostic and therapeutic radiopharmaceuticals backed by a vertically consolidated system of manufacturing facilities and radiopharmacies. Bayer AG is involved in its radiopharmaceutical portfolio, especially diagnostic imaging agents in the field of nuclear medicine. The collective partnership of these companies covers important areas of the nuclear medicine value chain, such as equipment, radiotracers, distribution, and clinical enablement.

Related Reports:

Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18], Alpha Emitters, Beta Emitters [Y-90, Lu-177], Brachytherapy), Application (Onco, Cardio, Neuro), Procedure, End User (Imaging Center, Hospital), & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com